Funder
Universitätsklinikum Heidelberg
Publisher
Springer Science and Business Media LLC
Reference40 articles.
1. Comis RL, Miller JD, Aldigé CR, Krebs L, Stoval E. Public attitudes toward participation in cancer clinical trials. J Clin Oncol. 2003;21(5):830–5.
2. Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. J Am Med Assoc. 2004;291(22):2720–6.
3. American Cancer Society Cancer Action Network. Barriers to patient enrollment in therapeutic clinical trials to cancer—a landscape report [Internet]. 2018 [cited 2023 May 30]. Available from: https://www.fightcancer.org/sites/default/files/National%20Documents/Clinical-Trials-Landscape-Report.pdf. Accessed 30 Jul 2023.
4. Cheng SK, Dietrich MS, Dilts DM. A sense of urgency: evaluating the link between clinical trial development time and the accrual performance of cancer therapy evaluation program (NCI-CTEP) sponsored studies. Clin Cancer Res. 2010;16(22):5557–63.
5. Zhang E, DuBois SG. Early termination of oncology clinical trials in the United States. Cancer Med. 2023;12(5):5517–25.